Yükleniyor... / Loading...
Oncology Care at Home for BMT and CAR-T
Bu çalışma, kemik iliği nakli (bone marrow transplant, BMT) veya CAR-T hücre tedavisi alan hastalarda teknoloji destekli evde onkoloji bakımının bakım eşgüdümünü ve yönetimini iyileştirme ile uygun tedaviye yönlendirme potansiyelini değerlendirmektedir. Program; uzaktan hasta izleme (BioIntelliSense BioButton cihazı), teletıp, çift yönlü hasta iletişim platformu (Memora Health) ve evde sağlık hizmetlerini kapsamaktadır. Çalışmaya, 18-89 yaş arasında, allojenik ya da otolog kemik iliği nakli veya CAR-T tedavisi almış ve sağlık ekibince ayaktan bakım için eve taburcu edilebilecek kadar stabil kabul edilen hastalar alınmıştır.
Yukarıdaki özet, resmî kaydın sade dile aktarılmış halidir. Orijinal İngilizce başlık referans için gösterilir.
Kriterler ClinicalTrials.gov kaydından orijinal İngilizce haliyle alınmıştır. Uygunluk kararını yalnızca deneyi yürüten ekip verebilir.
Inclusion Criteria: * Age 18 years to 89 years old * Bone marrow transplant recipients (allogeneic and autologous) or CAR-T patients * Determined by care provider to be stable for discharge to home setting for outpatient care according to clinical practice standard operating procedures (SOPs) * Residing in the Denver metro area for the duration of the study within 45 minutes of the AMC * Has in-home caregiver support 24/7 (i.e., does not live alone) * Has self-reported reliable telephone and home internet service and a stable wireless network * Patient agrees to not submerge the BioButton Rechargeable device in more than 3 feet of water or submerge for longer than 30 minutes at a time. * Patient owns or possesses, as the primary user with reliable daily access, a mobile device (iOS or Android) capable of running the study's mobile applications and accepting the terms and conditions * Patient has SMS texting capacity and an unlimited texting plan or other plan sufficient for study text messaging without undue patient burden * Patient is willing to complete and log a self-check of temperature twice daily and return the log to the study team at the end of the study * Patient is willing to be available for the duration of the study * Patient has access to reliable transportation to the hospital 24/7 Exclusion Criteria: * Patients will be excluded from study participation if the PI or designated care provider believes study participation would not be in the patient's best interest for clinical reasons. * Patients may also be excluded from study participation if in the opinion of the PI they have a medical condition that may impede their ability to adhere to the study protocol.